Latest News & Updates
Breaking News
3 hours ago
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Other trending news you may like to read
aTyr Pharma Secures FDA Type C Feedback, Plans June 2026 IND for Efzofitimod Phase 3 in Pulmonary Sarcoidosis
aTyr Pharma will submit a Phase 3 IND for efzofitimod in June 2026, using FVC as primary endpoint after FDA Type C meeting feedback.
Pharma Now Editorial Team
Elicio Therapeutics Plans End-of-Phase 2 FDA Meeting for ELI-002 7P Following Mid-2026 PDAC Readout
Elicio plans an End-of-Phase 2 FDA meeting for ELI-002 7P in KRAS-mutant PDAC following mid-2026 Phase 2 DFS data readout.
Pharma Now Editorial Team
Tonix Pharmaceuticals Launches TONMYA Commercially After First New Fibromyalgia Approval in 15 Years
Tonix's TONMYA logged 3,588 new patients and 5,400 prescriptions in its first full commercial quarter, with a GPO deal covering 35 million lives.
Pharma Now Editorial Team
Biomea Fusion Clears Chronic Tox Hurdle for Icovamenib, Enabling Extended Clinical Dosing in Diabetes Trials
Biomea Fusion completes chronic tox studies for icovamenib, unlocking extended clinical dosing and triggering IND amendment activity across T1D, T2D, and obesity programs.
Pharma Now Editorial Team
